Congress commits $6B to subsidize antibiotic makers—with a twist.

What it does

This bill creates a $6 billion federal program to pay pharmaceutical companies $75–$300 million per year for developing new antibiotics targeting drug-resistant infections. Companies must apply within 2 years of FDA approval, meet scoring criteria based on clinical benefit and innovation, maintain U.S. supply, track resistance data, and educate providers on appropriate use. The program also funds hospital and outpatient antibiotic stewardship programs and expands CDC surveillance of resistance trends.

Why we flagged it

The bill's operative mechanism is a guaranteed annual payment to drug manufacturers ($75–$300M per year, adjusted for inflation, reduced only by net U.S. sales). While framed as addressing antimicrobial resistance—a real public-health crisis—the payment structure is a de facto subsidy that decouples company revenue from market performance, shifting development risk to taxpayers.

What the text implies

• The payment formula (annual subsidy minus net U.S. sales revenue) creates a perverse incentive: companies profit most when they sell less, because the government payment remains high while sales revenue is subtracted. A company selling $50M in a year receives $225M–$250M in government payment; one selling $200M receives $75M–$100M. This inverts normal market discipline.
• Section 399PP–1(2) exempts the Advisory Group from FACA termination rules (Section 1013), meaning the committee has no automatic sunset and may persist indefinitely without congressional reauthorization, reducing oversight of the program's scoring and eligibility decisions.

The full analysis lists 5 implications of this text.

Who stands to gain

pharmaceutical companies developing antimicrobial drugs; biopharmaceutical manufacturers of novel antibiotics and antifungals